<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772887</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15090627</org_study_id>
    <nct_id>NCT02772887</nct_id>
  </id_info>
  <brief_title>Nutraceutical Citrulline in Pregnancy</brief_title>
  <official_title>Phase 1 Trial Citrulline and Type 2 Diabetes in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if oral of L-citrulline (3 grams/day) for 3 weeks
      provided in mid-pregnancy to pregnant women with type 2 diabetes will increase the plasma
      L-arginine/ADMA ratio, lower maternal blood pressure and increase maternal levels of
      placental growth factor (PlGF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pregnancy-specific syndrome preeclampsia is a leading cause of maternal and fetal
      morbidity and mortality. The underlying cause of preeclampsia is unknown, however several
      pre-existing maternal conditions are associated with an increased risk of preeclampsia
      including: diabetes, hypertension, renal dysfunction, obesity and history of preeclampsia.
      Specifically, the risk of preeclampsia is five times greater in women with diabetes.

      Several lines of evidence indicate that endothelial dysfunction is a central feature of the
      pathophysiology of preeclampsia. Asymmetric dimethylarginine (ADMA) is a methylated
      metabolite of the amino acid L-arginine and an endogenous inhibitor of nitric oxide synthase
      (NOS). High concentrations of ADMA contribute to endothelial dysfunction and ADMA inhibits
      angiogenesis and arteriogenesis, activities important in pregnancy and deficient in
      preeclampsia. ADMA concentrations are higher early in pregnancy among women who later develop
      preeclampsia. This protocol describes a randomized placebo-controlled trial of L-citrulline
      in 40 pregnant women with type 2 diabetes from approximately sixteen to nineteen weeks
      gestation, to determine whether L-citrulline supplementation increases the plasma
      L-arginine/ADMA ratio, lowers maternal blood pressure and increases a circulating marker of
      placental function (placental growth factor PLGF).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>approximately 20 weeks</time_frame>
    <description>research measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placental growth factor (PlGF)</measure>
    <time_frame>approximately 20 weeks</time_frame>
    <description>quantified by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral L-citrulline, 3 grams once per day for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 3 grams once per day for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Citrulline</intervention_name>
    <description>amino acid supplement</description>
    <arm_group_label>Citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy

          -  Type 2 diabetes with hemoglobin A1c &lt;8

          -  Gestational age at randomization between 14 and 16 weeks based on clinical information

          -  Maternal age between 14 and 40 years

        Exclusion Criteria:

          -  Chronic hypertension

          -  Major fetal anomaly

          -  Fetal demise

          -  Planned termination of the pregnancy

          -  Collagen vascular disease (autoimmune disease) on medication

          -  Renal disease

          -  Epilepsy or other seizure disorder

          -  Active or chronic liver disease

          -  Heart disease, known illicit drug or alcohol abuse during current pregnancy

          -  Already taking L-citrulline as a supplement (1gram/day or more)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert W Powers, PhD</last_name>
      <phone>412-641-6005</phone>
      <email>powersrw@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Arun Jeyabalan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Robert Powers</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>asymmetric dimethylarginine</keyword>
  <keyword>L-arginine</keyword>
  <keyword>L-citrulline</keyword>
  <keyword>placental growth factor (PlGF)</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

